These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29532176)

  • 21. Development and application of a multiroute physiologically based pharmacokinetic model for oxytetracycline in dogs and humans.
    Lin Z; Li M; Gehring R; Riviere JE
    J Pharm Sci; 2015 Jan; 104(1):233-43. PubMed ID: 25407474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Colistin treatment in carbapenem-resistant Acinetobacter baumannii pneumonia patients: Incidence of nephrotoxicity and outcomes.
    Kwon KH; Oh JY; Yoon YS; Jeong YJ; Kim KS; Shin SJ; Chung JW; Huh HJ; Chae SL; Park SY
    Int J Antimicrob Agents; 2015 Jun; 45(6):605-9. PubMed ID: 25772644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of Colistin Methansulphonate (CMS) and Colistin after CMS Nebulisation in Baboon Monkeys.
    Marchand S; Bouchene S; de Monte M; Guilleminault L; Montharu J; Cabrera M; Grégoire N; Gobin P; Diot P; Couet W; Vecellio L
    Pharm Res; 2015 Oct; 32(10):3403-14. PubMed ID: 26040660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of Polymyxins in Animals.
    Marchand S; Grégoire N; Couet W
    Adv Exp Med Biol; 2019; 1145():89-103. PubMed ID: 31364073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of colistin after nebulization or intravenous administration of colistin methanesulphonate (Colimycin®) to cystic fibrosis patients.
    Magréault S; Mankikian J; Marchand S; Diot P; Couet W; Flament T; Grégoire N
    J Cyst Fibros; 2020 May; 19(3):421-426. PubMed ID: 31501050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients.
    Garonzik SM; Li J; Thamlikitkul V; Paterson DL; Shoham S; Jacob J; Silveira FP; Forrest A; Nation RL
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3284-94. PubMed ID: 21555763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and pharmacokinetic evaluation of intravenous colistin methanesulfonate sodium in Japanese healthy male subjects.
    Mizuyachi K; Hara K; Wakamatsu A; Nohda S; Hirama T
    Curr Med Res Opin; 2011 Dec; 27(12):2261-70. PubMed ID: 21995648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration.
    Karaiskos I; Friberg LE; Galani L; Ioannidis K; Katsouda E; Athanassa Z; Paskalis H; Giamarellou H
    Int J Antimicrob Agents; 2016 Sep; 48(3):337-41. PubMed ID: 27474468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population Pharmacokinetics of Intravenous Colistin in Pediatric Patients: Implications for the Selection of Dosage Regimens.
    Ooi MH; Ngu SJ; Chor YK; Li J; Landersdorfer CB; Nation RL
    Clin Infect Dis; 2019 Nov; 69(11):1962-1968. PubMed ID: 30722017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Different Component Contents of Colistin Methanesulfonate on the Pharmacokinetics of Prodrug and Formed Colistin in Human.
    Fan YX; Chen YC; Li Y; Yu JC; Bian XC; Li X; Li WZ; Guo BN; Wu HL; Liu XF; Wang Y; Xu XY; Hu JL; Wang JJ; Wu XJ; Cao GY; Wu JF; Xue CJ; Feng J; Zhang YY; Zhang J
    Pharm Res; 2021 Jan; 38(1):79-87. PubMed ID: 33496870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa.
    Sorlí L; Luque S; Segura C; Campillo N; Montero M; Esteve E; Herrera S; Benito N; Alvarez-Lerma F; Grau S; Horcajada JP
    BMC Infect Dis; 2017 Jan; 17(1):11. PubMed ID: 28056821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing.
    Mohamed AF; Cars O; Friberg LE
    J Antimicrob Chemother; 2014 May; 69(5):1350-61. PubMed ID: 24474432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B.
    Rigatto MH; Oliveira MS; Perdigão-Neto LV; Levin AS; Carrilho CM; Tanita MT; Tuon FF; Cardoso DE; Lopes NT; Falci DR; Zavascki AP
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2443-9. PubMed ID: 26856846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections.
    Yapa SWS; Li J; Porter CJ; Nation RL; Patel K; McIntosh MP
    Antimicrob Agents Chemother; 2013 Oct; 57(10):5087-95. PubMed ID: 23917323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Pharmacokinetics and Pharmacodynamics of Colistin.
    Grégoire N; Aranzana-Climent V; Magréault S; Marchand S; Couet W
    Clin Pharmacokinet; 2017 Dec; 56(12):1441-1460. PubMed ID: 28550595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study.
    Phe K; Shields RK; Tverdek FP; Aitken SL; Guervil DJ; Lam WM; Musgrove RJ; Luce AM; Tam VH
    J Antimicrob Chemother; 2016 Dec; 71(12):3585-3587. PubMed ID: 27543655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?
    Zavascki AP; Nation RL
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of colistin methanesulfonate (CMS) in healthy Chinese subjects after single and multiple intravenous doses.
    Zhao M; Wu XJ; Fan YX; Zhang YY; Guo BN; Yu JC; Cao GY; Chen YC; Wu JF; Shi YG; Li J; Zhang J
    Int J Antimicrob Agents; 2018 May; 51(5):714-720. PubMed ID: 29305956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dosing guidance for intravenous colistin in critically-ill patients.
    Nation RL; Garonzik SM; Thamlikitkul V; Giamarellos-Bourboulis EJ; Forrest A; Paterson DL; Li J; Silveira FP
    Clin Infect Dis; 2017 Mar; 64(5):565-571. PubMed ID: 28011614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Model-Based Approach To Assessing the Importance of Intracellular Binding Sites in Doxorubicin Disposition.
    Dubbelboer IR; Lilienberg E; Sjögren E; Lennernäs H
    Mol Pharm; 2017 Mar; 14(3):686-698. PubMed ID: 28182434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.